Article type: Editorial

Home Page URL: https://www.alliedacademies.org/hematology-blood-disorders/

Anticoagulants in action: Managing clotting disorders in clinical practice.

Jackson Wang*

Department of medicine, Creighton University Omaha, United States

Correspondence to: Rini Santoso, Department of medicine, Creighton University Omaha, United States, E-mail: Wang66@tsinghua.edu.cn

Received: 02-Jun-2025, Manuscript No. aahbd-25-171218; **Editor assigned:** aahbd-25-171218, PreQC No. aahbd-25-171218 (PQ); **Reviewed:** 17-Jun-2025, QC No. aahbd-25-171218; **Revised**: 24-Jun-2025, Manuscript No. aahbd-25-171218 (R); **Published**: 30-Jun-2025, DOI: 10.35841/aahbd-8.2.221.

Introduction

Blood clotting is a vital physiological process that prevents excessive bleeding following injury. However, when clotting occurs inappropriately within blood vessels, it can lead to life-threatening conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and myocardial infarction. Anticoagulants—drugs that inhibit various components of the coagulation cascade—play a central role in managing these disorders. Their judicious use in clinical practice requires a nuanced understanding of pharmacology, patient-specific factors, and evolving therapeutic strategies [1].

The coagulation cascade is a complex network of enzymatic reactions that culminate in the formation of fibrin, the protein that stabilizes blood clots. It involves two pathways—intrinsic and extrinsic—that converge on the activation of factor X, leading to thrombin generation and fibrin formation. Anticoagulants target different steps in this cascade to prevent clot formation or propagation [2].

Anticoagulants are broadly categorized into: Unfractionated heparin (UFH) and low-molecular-weight heparins (LMWHs) enhance antithrombin III activity, inhibiting thrombin and factor Xa. They are used for rapid anticoagulation in hospitalized patients. Warfarin inhibits synthesis of vitamin K-dependent clotting factors (II, VII, IX, X). It requires regular monitoring of the international normalized ratio (INR) due to its narrow therapeutic window. include direct thrombin inhibitors (dabigatran) and factor Xa inhibitors (rivaroxaban, apixaban, edoxaban). DOACs offer predictable pharmacokinetics and do not require routine monitoring [3].

Agents like argatroban and bivalirudin are used in specific settings such as heparin-induced thrombocytopenia (HIT). Anticoagulants are prescribed for a range of thrombotic disorders: Includes DVT and PE. LMWHs and DOACs are preferred for initial and long-term treatment. AF increases stroke risk due to embolic events. DOACs have largely replaced warfarin for stroke prevention in non-valvular AF. VKAs remain the standard due to lack of efficacy data for DOACs in this population. LMWHs and DOACs are used, with considerations for bleeding risk and drug interactions. The primary challenge in anticoagulant therapy is balancing thrombosis prevention with bleeding risk. Major bleeding, including intracranial hemorrhage and gastrointestinal bleeding, can be fatal. Risk stratification tools such as HAS-BLED and CHA_2DS_2-VASc scores help guide therapy in AF patients [4].

Monitoring depends on the anticoagulant class: Requires INR monitoring. Reversal is achieved with vitamin K, prothrombin complex concentrate (PCC), or fresh frozen plasma. Monitored via activated partial thromboplastin time (aPTT). Protamine sulfate reverses its effects. Routine monitoring is not required, but anti-factor Xa levels or thrombin time may be used in special cases. Reversal agents include idarucizumab for dabigatran and andexanet alfa for factor Xa inhibitors. Anticoagulant management must be tailored for: LMWHs are preferred due to safety profile; warfarin is teratogenic. DOACs require dose adjustment or avoidance depending on renal function. Increased bleeding risk necessitates careful dose selection and monitoring [5].

Conclusion

These agents aim to reduce thrombosis with minimal bleeding risk and are currently under investigation. Driven algorithms are being explored

Citation: Wang J. Anticoagulants in action: Managing clotting disorders in clinical practice. Hematol Blood Disord. 2025;8(2):221.

to personalize anticoagulant therapy, predict bleeding risk, and optimize dosing. DOACs are being studied for use in peripheral artery disease and post-surgical thromboprophylaxis. Ensuring patients understand dosing, adherence, and signs of bleeding. Warfarin interacts with many drugs and foods; DOACs have fewer interactions but still require vigilance. Temporary use of heparin during warfarin initiation or interruption for procedures. Anticoagulants are indispensable in modern medicine, offering life-saving benefits in clotting disorders. Their use demands a careful balance between efficacy and safety, guided by clinical judgment, patient-specific factors, and evolving evidence. As newer agents and technologies emerge, the future of anticoagulation promises greater precision and improved outcomes.

References

1. Lennard AL, Storey N, Dickinson AM, et al. Collection of Philadelphia-negative peripheral blood progenitor cells in unselected patients with chronic granulocytic leukaemia.. Leukemia. 1998;12(5):746-52.
2. Duncan N, Hewetson M, Powles R, et al. An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma. Bone Marrow Transplant. 1996;18(6):1175-8.
3. Hj K. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. Vox Sang. 1998;74:321-9.
4. Hortobagyi GN, Buzdar AU, Theriault RL, et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst. 2000;92(3):225-33.
5. Attal M, Harousseau JL, Stoppa AM, et al. .A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335(2):91-7.

Citation: Wang J. Anticoagulants in action: Managing clotting disorders in clinical practice. Hematol Blood Disord. 2025;8(2):221.